Literature DB >> 26822194

Salivary duct carcinoma: a Danish national study.

Helle Breinholt1, Mohammad Talal Elhakim1, Christian Godballe1, Lisbeth Juhler Andersen2, Hanne Primdahl3, Claus A Kristensen4, Kristine Bjørndal5.   

Abstract

BACKGROUND: To present the first national series of salivary duct carcinoma patients, including survival rates and an analysis of prognostic factors.
METHODS: By merging three Danish nationwide registries that encompass an entire population, 34 patients diagnosed with salivary duct carcinoma from 1990 to 2005 were identified. Histological slides were reviewed, and data concerning demographics, tumour site, clinical stage, treatment profiles and follow-up were retrieved. Survival estimates and prognostic factors were evaluated by comparing Kaplan-Meier plots using the Mantel-Haenszel log-rank test.
RESULTS: Salivary duct carcinoma showed an incidence of 0.04/100.000 inhabitants/year. Distant recurrence was seen in 52% of patients. Five-year overall survival, disease-specific survival and recurrence-free survival were 32%, 42% and 35%, respectively. Univariate analyses suggested that overall stage (III/IV) and vascular invasion have a negative impact on all survival measures. Involved resection margins correlated with a poorer overall survival and disease-specific survival, whereas adjuvant radiotherapy improved overall survival and recurrence-free survival.
CONCLUSIONS: Salivary duct carcinoma incidence averages to two episodes per year in the entire Kingdom of Denmark. With half of patients in this study experiencing distant recurrences and only a third surviving at 5 years, prognosis is dismal. Advanced overall stage, vascular invasion and involved resection margins all seem to correlate with a poorer survival, while adjuvant radiotherapy significantly improved outcome. Extensive T-site surgery, neck dissection and adjuvant radiotherapy are therefore recommended.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  national; prognostic factors; salivary duct carcinoma; survival

Mesh:

Year:  2016        PMID: 26822194     DOI: 10.1111/jop.12426

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  6 in total

1.  Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.

Authors:  Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-21       Impact factor: 2.503

2.  Clinical value of adjuvant therapy on the prognosis of ductal carcinoma of the major salivary gland: a large-scale cohort study.

Authors:  Di Zhang; Lixi Li; Tingyu Wen; Fei Ma
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-29       Impact factor: 3.236

Review 3.  Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Authors:  Nicole C Schmitt; Hyunseok Kang; Arun Sharma
Journal:  Oral Oncol       Date:  2017-09-21       Impact factor: 5.337

4.  Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma.

Authors:  Sebastian Adeberg; Paul Windisch; Felix Ehret; Melissa Baur; Sati Akbaba; Thomas Held; Denise Bernhardt; Matthias F Haefner; Juergen Krauss; Steffen Kargus; Christian Freudlsperger; Peter Plinkert; Christa Flechtenmacher; Klaus Herfarth; Juergen Debus; Stefan Rieken
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

5.  A population-based competing risk survival analysis of patients with salivary duct carcinoma.

Authors:  Jianchuan Ran; Huihui Zou; Xiaoye Li; Feng Guo; Wenguang Xu; Wei Han
Journal:  Ann Transl Med       Date:  2020-11

6.  The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan.

Authors:  Kimihide Kusafuka; Yoko Sato; Eiji Nakatani; Satoshi Baba; Matsuyoshi Maeda; Koji Yamanegi; Kaori Ueda; Hiroshi Inagaki; Yoshiro Otsuki; Naoto Kuroda; Kensuke Suzuki; Hiroshi Iwai; Yoshiaki Imamura; Junya Itakura; Shoji Yamanaka; Hideaki Takahashi; Ichiro Ito; Takumi Akashi; Tsutomu Daa; Mei Hamada; Masanori Yasuda; Ryo Kawata; Hidetaka Yamamoto; Yuri Tachibana; Junya Fukuoka; Aya Muramatsu; Kazumori Arai; Makoto Suzuki
Journal:  Head Neck       Date:  2022-03-29       Impact factor: 3.821

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.